Prognostic value of serum analyses of S-100β protein in malignant melanoma

Melanoma Research

Volumn 6, Issue 2, 1996, Pages 133-137

  Von Schoultz, E ^a   Hansson, L O ^a   Djureen, E ^a   Hansson, J ^a   Karnell R ^a   Nilsson, B ^a   Stigbrand, T ^b   Ringborg, U ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

Author keywords

malignant melanoma; prognosis; S 100 protein

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN ANTIBODY; PROTEIN S 100;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNORADIOMETRIC ASSAY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; SERUM;

EID: 0029758684     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199604000-00008     Document Type: Article

References (32)

1. Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Commun 1965; 19: 739-744.
2. Isobe T, Okuyama T. The amino acid sequence of S 100 protein (PAP-1b protein) and its relationship to calcium binding proteins. Eur J Biochem 1978; 89: 379-388.
3. Baudier J, Briving C, Dienum J, et al. Effect of S 100 protein and calmodulin on calcium-induced disassembly of brain microtubule proteins in vitro. FEBS Lett 1982; 147: 165-168.
4. Donato R. Perspectives in S-100 protein biology. Review article. Cell Calcium 1991; 12: 713-726.
5. Kligman D, Hilt DC. The S 100 protein family. Trends Biochem Sci 1988; 13: 437-443.
6. Takahashi K, Isobe T, Ohtsuki Y, et al. Immunohistochemical localization and distribution of S100 proteins in the human lymphoreticular system. Am J Pathol 1984; 116: 497-503.
7. Nakajima T, Sato Y, Watanabe S, et al. Immunoelectron microscopical demonstration of S100 protein in epidermal Langerhans' cells. Biomed Res 1982; 3: 226-231.
8. Persson L, Härdemark HG, Gustavsson J, et al. S-100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987; 18: 911-918.
9. Gatter KC, Ralfkiaer E, Skinner J, et al. An immuncytochemical study of malignant melanoma and its differential diagnosis from other malignant tumours. J Clin Pathol 1985; 38: 1353-1357.
10. Carrel S, Rimoldi D. Melanoma-associated antigens. Eur J Cancer 1993; 29A: 1903-1907.
11. Paul E, Wen DR, Cochran AJ. Variations in S-100 protein expression in naevo-cellular naevi may be related to metabolic activity. Br J Dermatol 1987; 116: 371-378.
12. Cho KH, Hashimoto K, Taniguchi Y, et al. Immunohistochemical study of melanocytic naevus and malignant melanoma with monoclonal antibodies against S-100 subunits. Cancer 1990; 66: 765-771.
13. Ketcham AS, Moffat FL, Balch CM. Classification and staging. In: CM Balch, AN Houghton, GW Milton, AJ Sober and S-j Soong, eds. Cutaneous Melanoma (2nd ed.) Philadelphia: JB Lippincott, 1992: 213-220.
14. Nyberg L, Urdal P, Skogseid IM, et al. S-100 in human serum as a marker for brain damage. Presented at the 15th Meeting of the European Neuroscience Association, Munich, Germany, 1992.
15. Cox DR. Regression models and life-tables (with discussion). J Roy Statist Soc B 1972; 34: 187-220.
16. Peto R, Pick MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977; 35: 1-38.
17. Smoller BR. Immunohistochemistry in the diagnosis of malignant melanoma. Clinics Dermatol 1991; 9: 235-241.
18. The Swedish National Board of Health and Welfare. Cancer Incidence in Sweden, 1991.
19. Hornef S, Lux J, Rassner G. Neuron-specific enolase (NSE) - a suitable tumor marker in malignant melanoma? Hautarzt 1992; 43: 77-80.
20. Couvreur R, Joos G, Geerts ML, et al. Neurone-specific enolase as serum marker for malignant melanoma. Lancet 1993; 342: 985-990.
21. Schutter EM, Visser JJ, van Kamp GJ, et al. The utility of lipid-associated sialic acid (LASA or LSA) as a serum marker for malignancy. A review of the literature. Tumour Biol 1992; 13: 121-132.
22. Rorsman H, Agrup G, Hansson C, Rosengren E. Biochemical recorders of malignant melanoma. In: R.M. Mackie, ed. Pigment Cell. Basel: Karger, 1983; 6: 93-115.
23. Sonesson B, Eide S, Ringborg U, et al. Tyrosinase activity in the serum of patients with malignant melanoma. Melanoma Res, submitted.
24. Horikoshi T, Ito S, Wakamatsu K, et al. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73: 629-636.
25. Smith B, Selby P, Southgate J, et al. Detection of melanoma cells in peripheral blood by means of reverse transcriptase and polymerase chain reaction. Lancet 1991; 338: 1227-1229.
26. Baudier J, Delphin C, Grunwald D, et al. Characterization of the tumor suppressor protein p53 as a protein kinase C substrate and a S-100/β-binding protein. Proc Natl Acad Sci USA 1992; 89: 1627-1631.
27. Bonnin JM, Rubinstein LJ. Immunohistochemistry of central nervous system tumors: its contribution to neurosurgical diagnosis. Neurosurgery 1984; 60: 1121-1133.
28. Nakamura Y, Becker LE, Marks A. S 100 protein in tumors of cartilage and bone: an immunohistochemical study. Cancer 1983; 52: 1820-1824.
29. Nakajima T, Watanabe S, Sato Y, et al. An immunoperoxidase study of S 100 protein distribution in normal and neoplastic tissues. Am J Surg Pathol 1982; 7: 715-727.
30. Mani S, Poo W-J, Cuny C. S 100 as a potential serum marker in metastatic melanoma. Proc Am Soc Clin Oncol 1994; 13: 398-402.
31. Fagnart OC, Sindic CJ, Laterre C. Particle counting immunoassay of S 100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 1988; 34: 1387-1391.
32. Bei Guo H, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S 100 in metastatic malignant melanoma. Eur J Cancer 1995; 31A: 924-928.